Literature DB >> 15579769

Deregulation of estrogen receptor coactivator proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor in human endometrial tumors.

Ratna K Vadlamudi1, Seetharaman Balasenthil, Russell R Broaddus, Jan-Ake Gustafsson, Rakesh Kumar.   

Abstract

Proline-, glutamic acid-, and leucine-rich protein-1)PELP1/MNAR [modulator of nongenomic activity of estrogen receptor (ER)], a novel coregulatory protein, modulates genomic as well as nongenomic activity of ERs. We characterized the expression and localization of PELP1 in both benign and cancerous endometrium. Our results suggest that PELP1 is expressed in all stages of endometrium; however, this protein exhibits distinct localization depending on the phase. PELP1 is expressed in both the stroma and epithelial cells. Using the Ishikawa endometrial cancer model cell line and ER subtype-specific ligands, we found that PELP1 functionally interacts with both ERalpha and ERbeta and enhances their transcriptional responses. However, in endometrial cancer cells, endogenous PELP1 is also required for optimal ligand-mediated transcription and proliferation responses. PELP1 promoted a tamoxifen-mediated agonistic action in endometrial, but not in breast cancer cells. PELP1 expression and localization are widely deregulated in endometrial cancers. In addition, PELP1 and ERbeta were localized predominantly in the cytoplasm of high-grade endometrial tumors. Our results suggest that PELP1 plays an essential role in the proliferation of cancerous endometrial cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15579769      PMCID: PMC1262662          DOI: 10.1210/jc.2004-0909

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  36 in total

Review 1.  Nuclear receptor coregulators: cellular and molecular biology.

Authors:  N J McKenna; R B Lanz; B W O'Malley
Journal:  Endocr Rev       Date:  1999-06       Impact factor: 19.871

2.  Mitochondrial localization of estrogen receptor beta.

Authors:  Shao-Hua Yang; Ran Liu; Evelyn J Perez; Yi Wen; Stanley M Stevens; Thomas Valencia; Anne-Marie Brun-Zinkernagel; Laszlo Prokai; Yvonne Will; James Dykens; Peter Koulen; James W Simpkins
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-15       Impact factor: 11.205

Review 3.  The estrogen receptor family.

Authors:  M Warner; S Nilsson; J A Gustafsson
Journal:  Curr Opin Obstet Gynecol       Date:  1999-06       Impact factor: 1.927

4.  Nongenomic effects of 17beta-estradiol in human platelets: potentiation of thrombin-induced aggregation through estrogen receptor beta and Src kinase.

Authors:  Laura Moro; Stefania Reineri; Daniela Piranda; Daniela Pietrapiana; Paolo Lova; Alessandra Bertoni; Andrea Graziani; Paola Defilippi; Ilaria Canobbio; Mauro Torti; Fabiola Sinigaglia
Journal:  Blood       Date:  2004-06-15       Impact factor: 22.113

5.  Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance.

Authors:  Rachel Schiff; Suleiman A Massarweh; Jiang Shou; Lavina Bharwani; Syed K Mohsin; C Kent Osborne
Journal:  Clin Cancer Res       Date:  2004-01-01       Impact factor: 12.531

6.  Activities of estrogen receptor alpha- and beta-selective ligands at diverse estrogen responsive gene sites mediating transactivation or transrepression.

Authors:  William R Harrington; Shubin Sheng; Daniel H Barnett; Larry N Petz; John A Katzenellenbogen; Benita S Katzenellenbogen
Journal:  Mol Cell Endocrinol       Date:  2003-08-29       Impact factor: 4.102

7.  Expression of steroid receptor coactivators and corepressors in human endometrial hyperplasia and carcinoma with relevance to steroid receptors and Ki-67 expression.

Authors:  Junko Uchikawa; Tanri Shiozawa; Hsien-Chang Shih; Tsutomu Miyamoto; Yu-Zhen Feng; Hiroyasu Kashima; Kenji Oka; Ikuo Konishi
Journal:  Cancer       Date:  2003-11-15       Impact factor: 6.860

8.  Characterization of the interactions of estrogen receptor and MNAR in the activation of cSrc.

Authors:  Frank Barletta; Chi-Wai Wong; Chris McNally; Barry S Komm; Benita Katzenellenbogen; Boris J Cheskis
Journal:  Mol Endocrinol       Date:  2004-02-12

Review 9.  Novel non-transcriptional mechanisms for estrogen receptor signaling in the cardiovascular system. Interaction of estrogen receptor alpha with phosphatidylinositol 3-OH kinase.

Authors:  Tommaso Simoncini; Letizia Fornari; Paolo Mannella; Gaetano Varone; Antonella Caruso; James K Liao; Andrea R Genazzani
Journal:  Steroids       Date:  2002-11       Impact factor: 2.668

Review 10.  Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy.

Authors:  Wenlin Shao; Myles Brown
Journal:  Breast Cancer Res       Date:  2003-11-07       Impact factor: 6.466

View more
  37 in total

1.  Regulation of aromatase induction by nuclear receptor coregulator PELP1.

Authors:  Ratna K Vadlamudi; Rajib Rajhans; Dimple Chakravarty; Binoj C Nair; Sujit S Nair; Dean B Evans; Shiuan Chen; Rajeshwar Rao Tekmal
Journal:  J Steroid Biochem Mol Biol       Date:  2009-09-30       Impact factor: 4.292

2.  PELP1 signaling contributes to medulloblastoma progression by regulating the NF-κB pathway.

Authors:  Yiliao Luo; Mengxing Li; Uday P Pratap; Suryavathi Viswanadhapalli; Junhao Liu; Prabhakar P Venkata; Kristin A Altwegg; Bridgitte E Palacios; Xiaonan Li; Yihong Chen; Manjeet K Rao; Andrew J Brenner; Gangadhara R Sareddy; Ratna K Vadlamudi
Journal:  Mol Carcinog       Date:  2019-12-24       Impact factor: 4.784

3.  Increased PELP1 expression in rat periodontal ligament tissue in response to estrogens treatment.

Authors:  Jing Wang; Qiang Zhu; Shujun Song; Jun Dong; Lixin Shi; Ran Tao; Yin Ding; Baofa Hong
Journal:  J Mol Histol       Date:  2013-02-24       Impact factor: 2.611

Review 4.  Minireview: Deciphering the Cellular Functions of PELP1.

Authors:  Preethi Ravindranathan; Carol A Lange; Ganesh V Raj
Journal:  Mol Endocrinol       Date:  2015-07-09

5.  Therapeutic significance of estrogen receptor β agonists in gliomas.

Authors:  Gangadhara R Sareddy; Binoj C Nair; Vijay K Gonugunta; Quan-guang Zhang; Andrew Brenner; Darrell W Brann; Rajeshwar Rao Tekmal; Ratna K Vadlamudi
Journal:  Mol Cancer Ther       Date:  2012-03-21       Impact factor: 6.261

6.  Nuclear receptor liver receptor homologue 1 (LRH-1) regulates pancreatic cancer cell growth and proliferation.

Authors:  Cindy Benod; Maia V Vinogradova; Natalia Jouravel; Grace E Kim; Robert J Fletterick; Elena P Sablin
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-26       Impact factor: 11.205

7.  Proline-, glutamic acid-, and leucine-rich protein-1 is essential in growth factor regulation of signal transducers and activators of transcription 3 activation.

Authors:  Bramanandam Manavathi; Sujit S Nair; Rui-An Wang; Rakesh Kumar; Ratna K Vadlamudi
Journal:  Cancer Res       Date:  2005-07-01       Impact factor: 12.701

8.  Proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor enhances androgen receptor functions through LIM-only coactivator, four-and-a-half LIM-only protein 2.

Authors:  Sujit S Nair; Zhiyong Guo; Judith M Mueller; Shahriar Koochekpour; Yun Qiu; Rajeshwar Rao Tekmal; Roland Schüle; Hsing-Jien Kung; Rakesh Kumar; Ratna K Vadlamudi
Journal:  Mol Endocrinol       Date:  2006-12-27

Review 9.  PELP1: A novel therapeutic target for hormonal cancers.

Authors:  Dimple Chakravarty; Rajeshwar Rao Tekmal; Ratna K Vadlamudi
Journal:  IUBMB Life       Date:  2010-03       Impact factor: 3.885

10.  Peptidomimetic targeting of critical androgen receptor-coregulator interactions in prostate cancer.

Authors:  Preethi Ravindranathan; Tae-Kyung Lee; Lin Yang; Margaret M Centenera; Lisa Butler; Wayne D Tilley; Jer-Tsong Hsieh; Jung-Mo Ahn; Ganesh V Raj
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.